News | August 12, 2011

U.K.'s First Total Artificial Heart Patient Discharged Using Freedom Portable Driver

August 12, 2011 — SynCardia Systems Inc., manufacturer of the temporary Total Artificial Heart (TAH), said Aug. 2, Papworth Hospital in Cambridge discharged the United Kingdom's first TAH patient. He was sent home to wait for a matching donor heart with his wife and 5-year-old son using the Freedom portable driver.

"Two years ago I was cycling nine miles to work and nine miles back every day, but by the time I was admitted to hospital, I was struggling to walk even a few yards," said patient Matthew Green. "I am really excited about going home and just being able to do the everyday things that I haven't been able to do for such a long time, such as playing in the garden with my son and cooking a meal for my family."

Green, 40, suffered from arrhythmogenic right ventricular cardiomyopathy (ARVC), a heart muscle disease resulting in arrhythmia, heart failure and sudden death. His health had been declining over recent years, with a heart transplant being his only option.

"Matthew's condition was deteriorating rapidly and we discussed with him the possibility of receiving this device, because without it he may not have survived the wait until a suitable donor heart could be found for him," said Steven Tsui, consultant cardiothoracic surgeon and director of the transplant service. "The operation went extremely well and Matthew has made an excellent recovery."

On June 9, Green became the first patient in the United Kingdom to receive the Total Artificial Heart. Two months later, he was discharged from the hospital using the Freedom portable driver. Weighing 13.5 pounds, including two onboard lithium-ion batteries, it is the world's first wearable portable driver designed to power the TAH both inside and outside the hospital. The driver is CE approved for use in Europe and undergoing a U.S. Food and Drug Administration (FDA)-approved investigational device exemption (IDE) clinical study in the United States.

Papworth Hospital is the first and only hospital in the UK certified to implant the TAH. The hospital performed the UK's first heart transplant in 1979 and has been using mechanical devices to support patients with end-stage heart failure since the 1980s.

For more information:

Related Content

Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD) | June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD) | May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Videos | Ventricular Assist Devices (VAD) | April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD) | April 03, 2017
Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing...
Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD) | March 09, 2017
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from...
Impella 2.5 heart pump, high-risk PCI, HRPCI, acute kidney injury risk, AKI, Circulation Research study, Abiomed
News | Ventricular Assist Devices (VAD) | March 09, 2017
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during...
Overlay Init